Myriad Genetics, in collaboration with SciencewerkeDX organised a series of talks in Jan 2015 to raise awareness of hereditary cancer.
Our speaker, Karen Copeland is the director of International Medical Affairs, Myriad Genetics GmbH and also a certified genetic counsellor.
Myriad Genetics today announced it has received approval from the US Food and Drug Administration for BRACAnalysis CDx™ as a companion diagnostic for AstraZeneca’s Lynparza™ (olaparib), a new drug for advanced ovarian cancer associated with BRCA genes.
Deficits in Children with Autism
Children with autism experience deficits in a type of immune cell that protects the body from infection. Called granulocytes, the cells exhibit one-third the capacity to fight infection and protect the body from invasion compared with the same cells in children who are developing normally.
CDx Lab in Europe
Myriad Genetics announced today that it has established a European laboratory that will offer its Tumor BRACAnalysis CDx test to guide treatment with PARP inhibitors, namely AstraZeneca’s olaparib.
NEW YORK (GenomeWeb) – A group of experts has recommended that newly diagnosed colorectal cancer patients should receive genetic tests to identify which ones may have Lynch syndrome, the American Gastroenterological Association said today.